Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:46:54 EDT Mon 20 May 2024
Enter Symbol
or Name
USA
CA



News for U:TPST from 2023-05-21 to 2024-05-20 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-09 16:29U:TPSTNews ReleaseTempest Reports First Quarter 2024 Financial Results and Provides Business Update
2024-04-26 16:05U:TPSTNews ReleaseTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-04-09 08:00U:TPSTNews ReleaseTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
2024-04-04 08:00U:TPSTNews ReleaseTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
2024-03-19 16:26U:TPSTNews ReleaseTempest Reports Year End 2023 Financial Results and Provides Business Update
2024-03-12 08:00U:TPSTNews ReleaseTempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
2024-03-05 16:30U:TPSTNews ReleaseTempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
2024-02-26 08:00U:TPSTNews ReleaseTempest to Present at the 44th Annual TD Cowen Healthcare Conference
2024-02-02 16:30U:TPSTNews ReleaseTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 16:05U:TPSTNews ReleaseTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-12-01 16:16U:TPSTNews ReleaseTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-20 08:00U:TPSTNews ReleaseTempest to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-08 17:18U:TPSTNews ReleaseTempest Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-10-11 08:01U:TPSTNews ReleaseTempest Adopts Limited Duration Stockholder Rights Plan
2023-10-11 08:00U:TPSTNews ReleaseTempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
2023-10-10 16:05U:TPSTNews ReleaseTempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
2023-09-19 08:00U:TPSTNews ReleaseTempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
2023-09-05 08:00U:TPSTNews ReleaseTempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 16:14U:TPSTNews ReleaseTempest Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-19 08:00U:TPSTNews ReleaseTempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
2023-05-31 16:05U:TPSTNews ReleaseTempest to Present at the Jefferies Global Healthcare Conference
2023-05-25 17:00U:TPSTNews ReleaseTempest to Present Phase 1 Monotherapy and Combination Data at ASCO ‚  for TPST-1495 in Patients with Advanced Cancers